Pfizer settles Rezulin product liability litigation
Executive SummaryPfizer has settled thousands of personal injury claims alleging the diabetes drug Rezulin (troglitazone) caused liver damage. The number of claims and the size of the settlement are confidential. However, Bloomberg reported that the company is paying $750 million to settle 35,000 claims. The company had set aside $975 million in 2003 for the litigation. Pfizer said the multidistrict litigation is now resolved and there are only a handful of cases remaining in state court, which it expects will be dismissed. Pfizer withdrew Rezulin from the market in 2000 after people taking the drug experienced liver failure
You may also be interested in...
As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.